Share this article on:

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection

Nüesch, Retoa,b; Ananworanich, Jintanata; Srasuebkul, Preeyapornc; Chetchotisakd, Ploenchand; Prasithsirikul, Wisite; Klinbuayam, Wiratf; Mahanontharit, Apichaa; Jupimai, Thidarata; Ruxrungtham, Kiata; Hirschel, Bernardg

doi: 10.1097/QAD.0b013e3282f303bf
Research Letters

Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.

aHIV-NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand

bOutpatient Clinic of Internal Medicine and Division of Infectious Diseases, University Hospital, Basel, Switzerland

cNational Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

dKhon Kaen University, Khon Kaen, Thailand

eBamrasnaradura Institute, Nonthaburi, Thailand

fSanpatong Hospital, Chiang Mai, Thailand

gDivision des Maladies Infectieuses, Geneva University Hospital, Geneva, Switzerland.

Received 11 June, 2007

Revised 25 September, 2007

Accepted 4 October, 2007

© 2008 Lippincott Williams & Wilkins, Inc.